Journal of Diabetes Research / 2017 / Article / Tab 1

Research Article

Fulminant Type 1 Diabetes in Children: A Multicenter Study in China

Table 1

Clinical features and laboratory tests of the three groups.

F1TD (9/14)Acute onset T1DM (83/99)Classical T1DM (375/504)FP

Duration of hyperglycemia (days)7 (2, 10)7 (5, 8)15 (10, 25)234.7360.000#
Age (year)2.00 (1.08, 6.51)6.11 (3.92, 9.50)6.92 (4.17, 10.03)14.0480.001#
BMI (kg/m2)16.12 (14.51, 19.55)15.01 (13.54, 17.29)14.87 (13.61, 16.64)4.6210.099
Family history01232
Flu-like symptoms17194057.7020.000#
Abdominal pain12326629.120.000#
Plasma glucose (mmol/L)25.10 (20.35, 30.00)22.99 (17.99, 30.89)21.78 (15.70, 28.96)9.7650.008#
HbA1C (%)7.2 ± 1.211.7 ± 2.111.8 ± 2.443.9090.000#
Peptide C (ng/mL)0.21 (0.09, 0.29)0.31 (0.11, 0.54)0.34 (0.13, 0.58)8.4640.015#
Diastolic blood pressure (mmHg)60 (60, 75)60 (60, 70)60 (60, 70)0.6190.734
Systolic pressure (mmHg)90 (70, 103)100 (90, 110)100 (90, 110)5.0260.081
pH7.23 (6.98, 7.34)7.28 (7.14, 7.38)7.32 (7.19, 7.40)14.3460.001#
HCO3 (mmol/L)8.20 (3.10, 16.85)13.10 (7.85, 18.90)16.30 (8.90, 22.10)16.6570.000#
k (mmol/L)4.41 (4.00, 4.91)4.10 (3.74, 4.60)4.12 (3.74, 4.51)3.7920.150
Na (mmol/L)135.6 (131.0, 138.0)135.0 (131.1, 136.9)135.0 (131.6, 138.0)2.6020.272
Cl (mmol/L)105.0 (98.0, 107.0)103.2 (100.0, 107.5)103.2 (99.2, 106.8)0.270.874
Plasma osmolal pressure (Mosm/L)284.8 (276.7, 293.1)288.8 (281.3, 297.0)289.4 (282.8, 296.6)2.8170.244
BUN (mmol/L)4.20 (2.70, 5.84)4.48 (3.39, 6.17)4.60 (3.50, 5.88)1.4370.488
CHO (mmol/L)3.59 (3.24, 5.05)3.99 (3.32, 4.98)4.12 (3.44, 4.90)1.0150.602
TG (mmol/L)1.24 (0.86, 1.59)1.45 (0.90, 2.52)1.10 (0.75, 1.83)14.5450.001#
AST (U/L)30 (22, 33)21 (15, 27)22 (18, 29)8.1590.017#
ALT (U/L)16 (12, 23)15 (12, 18)15 (12, 20)0.8080.668
Insulin dosage of ketoacidosis treatment (IU)11.93 (7.42, 31.35)13.20 (8.40, 25.89)14.43 (9.26, 28.00)1.3330.513
Time of ketoacidosis treatment (hour)15.0 (4.5, 21.5)9.3 (6.0, 15.6)10.0 (6.0, 16.5)1.0430.594

The statistical method used was analysis of variance. # represents .

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.